Suppr超能文献

新冠肺炎的潜在特效疗法。

Potential specific therapies in COVID-19.

机构信息

Internal Medicine Department, Amita-Presence Saint Joseph Hospital, Chicago, 2900 N Lakeshore Drive, Chicago, IL 60657, USA.

Internal Medicine Department, Louis A Weiss Memorial Hospital, Chicago, IL, USA.

出版信息

Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926853. doi: 10.1177/1753466620926853.

Abstract

COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection.

摘要

新冠疫情已经在全球蔓延,给世界各地的医疗保健系统带来了巨大压力。目前当务之急是寻找针对这种致命病毒的治疗方法。在本研究中,我们根据网上可获得的文献,综述了新冠疫情中常见的经验性治疗方法,重点关注了人类在严重急性呼吸系统综合征冠状病毒(SARS-COV-1)和其他病毒方面的治疗经验。恢复期血液制品是最有希望用于治疗新冠的方法。氯喹或羟氯喹(HCQ)、瑞德西韦和托珠单抗等也是有前途的潜在疗法,但它们仍需在随机临床试验(RCT)中进行测试。洛匹那韦-利托那韦在一项大型 RCT 中并未显示出益处。基于 SARS-COV-1 和中东呼吸综合征(MERS)感染患者的危害提示,不建议在新冠病毒肺炎中使用皮质类固醇,除非用于其他指征。

相似文献

1
Potential specific therapies in COVID-19.
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926853. doi: 10.1177/1753466620926853.
2
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.
5
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
6
Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Am J Emerg Med. 2020 Jul;38(7):1488-1493. doi: 10.1016/j.ajem.2020.04.035. Epub 2020 Apr 15.
7
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
J Infect Public Health. 2020 Oct;13(10):1405-1414. doi: 10.1016/j.jiph.2020.07.004. Epub 2020 Jul 13.
9
A global treatments for coronaviruses including COVID-19.
J Cell Physiol. 2020 Dec;235(12):9133-9142. doi: 10.1002/jcp.29785. Epub 2020 May 11.
10

引用本文的文献

1
COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.
Biomed Res Int. 2023 Aug 29;2023:1879554. doi: 10.1155/2023/1879554. eCollection 2023.
2
The role of the endothelium in severe acute respiratory syndrome coronavirus 2 infection and pathogenesis.
Curr Opin Physiol. 2023 Aug;34:100670. doi: 10.1016/j.cophys.2023.100670. Epub 2023 Apr 1.
3
Correlation between COVID-19 and hepatitis B: A systematic review.
World J Gastroenterol. 2022 Dec 14;28(46):6599-6618. doi: 10.3748/wjg.v28.i46.6599.
4
Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review.
Nutrients. 2021 May 4;13(5):1550. doi: 10.3390/nu13051550.
5
COVID-19 combined with liver injury: Current challenges and management.
World J Clin Cases. 2021 May 26;9(15):3487-3497. doi: 10.12998/wjcc.v9.i15.3487.
8
COVID-19 and cardiovascular diseases.
J Mol Cell Biol. 2021 Jul 6;13(3):161-167. doi: 10.1093/jmcb/mjaa064.
10
Treatment for COVID-19: An overview.
Eur J Pharmacol. 2020 Dec 15;889:173644. doi: 10.1016/j.ejphar.2020.173644. Epub 2020 Oct 11.

本文引用的文献

1
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
2
A human monoclonal antibody blocking SARS-CoV-2 infection.
Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
3
Effective treatment of severe COVID-19 patients with tocilizumab.
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
4
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.
Lancet Respir Med. 2020 Jun;8(6):539-541. doi: 10.1016/S2213-2600(20)30172-7. Epub 2020 Apr 15.
6
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
7
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
9
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
10
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验